World Cell and Gene Therapy Deals Analysis Report 2023: Deals Amounted to $40 Billion in 2022 - Companies Receive Large Amounts of Investments Despite a Decline from 2021 Levels of Investment
20 juin 2023 05h33 HE
|
Research and Markets
Dublin, June 20, 2023 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Market and Deals Analysis, 2023: Financings, Partnering, Mergers and Acquisitions, Tech Transfers, IPOs, and Other Deals" report...
UAE Gene Editing Technology Databook 2023: Compound Annual Growth of 8.4% Forecast During 2023-2027
13 juin 2023 04h03 HE
|
Research and Markets
Dublin, June 13, 2023 (GLOBE NEWSWIRE) -- The "UAE Gene Editing Technology Databook 2023" has been added to ResearchAndMarkets.com's offering.The UAE gene editing technology market is expected to...
Caribou Biosciences to Participate in Upcoming Investor Conferences
31 mai 2023 16h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...
Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
09 mai 2023 16h00 HE
|
Caribou Biosciences, Inc.
-- CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients...
Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board
08 mai 2023 09h00 HE
|
Caribou Biosciences, Inc.
-- Dr. Schuster is a world-renowned hematologist and pioneer in CAR-T cell therapy development -- BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a...
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
04 mai 2023 07h30 HE
|
Intellia Therapeutics, Inc.
Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023Plans to submit...
Caribou Biosciences to Participate in Upcoming Investor Conferences
01 mai 2023 16h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...
Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting
17 avr. 2023 13h30 HE
|
Caribou Biosciences, Inc.
-- CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML xenograft models -- -- CB-012 IND-enabling studies ongoing; IND submission in r/r AML...
Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
04 avr. 2023 08h00 HE
|
Caribou Biosciences, Inc.
-- CaMMouflage Phase 1 trial for CB-011 enrolling patients with r/r MM at dose level 1 -- BERKELEY, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading...
Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
29 mars 2023 08h00 HE
|
Caribou Biosciences, Inc.
-- CB-011 is designed to improve antitumor activity by cloaking the allogeneic CAR-T cells from immune-mediated rejection -- -- CB-011 is Caribou’s second program to enter the clinic from its...